Considérations pratiques pour l’utilisation des inhibiteurs du SGLT2 dans les maladies cardiovasculaires [Practical considerations in the use of SGLT2 inhibitors in cardiovascular diseases]
Fiche du document
26 mai 2021
- doi: 10.53738/REVMED.2021.17.740.1034
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2021.17.740.1034
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/34042339
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_7FA860CBBECC0
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Citer ce document
H. Lu et al., « Considérations pratiques pour l’utilisation des inhibiteurs du SGLT2 dans les maladies cardiovasculaires [Practical considerations in the use of SGLT2 inhibitors in cardiovascular diseases] », Serveur académique Lausannois, ID : 10.53738/REVMED.2021.17.740.1034
Métriques
Partage / Export
Résumé
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of drugs which offer cardiovascular (CV) and renal benefits. They are currently indicated as first-line treatments of type 2 diabetes mellitus (T2DM) in patients with CV disease, high CV risk, renal disease, or heart failure with reduced ejection fraction (HFrEF). Two randomized clinical trials have shown the benefits of dapagliflozin and empagliflozin in patients with HFrEF, regardless of the presence of T2DM. Despite an overall favorable safety profile, attention has to be paid to adverse events, such as an increased risk of euglycemic diabetic ketoacidosis and genital mycotic infections. We present an up-to-date narrative literature review of the physiological mechanisms of action, current indications, and side effects of SGLT2 inhibitors.